Metoprolol Succinate Amlodipine Tablet
Description
METROOT-AT
Metoprolol Succinate Extended Release 23.75 mg and Amlodipine 5 mg Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 23.75 mg
Amlodipine IP — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
METROOT-AT is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 23.75 mg and Amlodipine 5 mg, formulated for the effective management of hypertension, chronic stable angina, coronary artery disease, and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the long-acting vasodilatory action of Amlodipine, resulting in superior antihypertensive efficacy and enhanced cardiovascular protection.
Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, improves arterial compliance, reduces peripheral vascular resistance, and provides sustained blood pressure control throughout the dosing interval.
METROOT-AT is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, chronic stable angina, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control.
Technical Knowledge of Metoprolol Succinate Extended Release and Amlodipine
Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day.
Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval.
The combination of Metoprolol Succinate Extended Release and Amlodipine provides complementary antihypertensive mechanisms with additional anti-anginal and cardiovascular protective benefits.
Mechanism of Action
Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade.
Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive and anti-anginal action.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Reduces heart rate and myocardial workload
Supports cardiovascular protection
Improves vascular compliance
Reduces peripheral vascular resistance
Provides anti-anginal benefits
Suitable for long-term hypertension and cardiovascular management under medical supervision
Clinical Applications
METROOT-AT is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, chronic stable angina, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Metoprolol Succinate Extended Release and Amlodipine
Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Amlodipine is one of the most extensively prescribed calcium channel blockers worldwide and provides effective long-term blood pressure control and anti-anginal efficacy. The combination is widely recommended for patients requiring both blood pressure reduction and heart rate control with additional coronary protection.
Key Facts
Beta-blocker and calcium channel blocker combination therapy
Metoprolol Succinate Extended Release 23.75 mg for sustained heart rate control
Amlodipine 5 mg for sustained arterial vasodilation
Provides 24-hour antihypertensive and anti-anginal action
Effective in hypertension with coronary artery disease
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
METROOT-AT is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose METROOT-AT for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 23.75 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
METROOT-AT from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Amlodipine formulation.
